GIPC2

GIPC2 is a PDZ-domain scaffolding adaptor that couples transmembrane receptors and cytoplasmic enzymes to downstream signaling cascades in a context-dependent manner. Through its PDZ domain, GIPC2 directly binds Frizzled-7 to activate WNT-β-catenin signaling in prostate cancer cells (PMID:35347223), interacts with the IGF receptor to engage PI3K signaling during kidney morphogenesis (PMID:22689378), and associates with PKM2 to promote its nuclear translocation and subsequent SREBP1-driven adipogenesis (PMID:41500998). GIPC2 also partners with the nuclear protein NONO to co-regulate p27 transcription and suppresses MAPK/ERK and HIF-1α pathways in chromaffin cells, functioning as a tumor suppressor whose loss downstream of RET and SDHB oncogenic mutations drives pheochromocytoma-associated proliferation (PMID:33947839). Epigenetic silencing of GIPC2 by promoter methylation occurs in acute myeloid leukemia, where its re-expression induces apoptosis through PI3K/AKT pathway inhibition (PMID:37212125).

1. 2002 Low

   Identification of GIPC2 as a GIPC1 paralog with a conserved central PDZ domain established it as a candidate PDZ-scaffolding protein likely binding TGFβRIII- or Frizzled-class receptors, framing the key question of what ligands and pathways it engages.

   Evidence cDNA cloning and sequence analysis showing 62% PDZ domain identity to GIPC1

   PMID:11836570

   Open questions at the time

   • Prediction based solely on sequence homology; no direct binding data for GIPC2 itself
   • No functional or cellular assay performed
   • Tissue-level expression pattern not validated at the protein level
2. 2012 Medium

   The first functional role for GIPC2 was established in Xenopus kidney development, where gipc2 depletion caused pronephros defects and its binding to the IGF receptor coupled to PI3K signaling, revealing GIPC2 as a receptor-proximal adaptor linking growth factor input to organ morphogenesis.

   Evidence Morpholino knockdown in Xenopus with pronephros phenotype, rescue by constitutively active PI3K p110*, and Co-IP with IGFR

   PMID:22689378

   Open questions at the time

   • Morpholino off-target effects not fully excluded
   • Rescue by PI3K was partial, leaving other downstream effectors uncharacterized
   • Whether the mammalian GIPC2-IGFR interaction is conserved was not tested
3. 2021 Medium

   GIPC2 was placed as a tumor-suppressive node upstream of MAPK/ERK-p27 signaling in chromaffin cells: it partners with NONO to co-activate p27 transcription and suppresses ERK and HIF-1α, while oncogenic RET and SDHB mutations reduce GIPC2 expression to drive proliferation, defining its loss-of-function role in pheochromocytoma/paraganglioma pathogenesis.

   Evidence Co-IP of GIPC2–NONO, p27 promoter luciferase assays, genetic epistasis with RET/SDHB mutants in primary rat chromaffin cells and PC12 xenografts

   PMID:33947839

   Open questions at the time

   • The direct mechanism by which GIPC2 suppresses ERK phosphorylation is unknown
   • GIPC2–NONO interaction domain mapping not reported
   • Nuclear versus cytoplasmic site of GIPC2 action on transcription unclear
4. 2022 High

   Direct PDZ-domain–mediated binding of GIPC2 to Frizzled-7 was demonstrated, establishing GIPC2 as an activator of WNT-β-catenin signaling and an oncogenic driver of prostate cancer invasion, contrasting with its tumor-suppressive role in chromaffin cells and showing its context-dependent signaling output.

   Evidence Reciprocal Co-IP with PDZ domain mutagenesis, knockdown/overexpression in vitro and in vivo tumor models

   PMID:35347223

   Open questions at the time

   • Structural basis of the GIPC2 PDZ–Frizzled-7 interaction not resolved
   • Whether exosomal GIPC2 acts through the same Fzd7-WNT axis in recipient cells is unclear
   • How GIPC2 switches between tumor-suppressive and oncogenic outputs in different tissues is not mechanistically explained
5. 2023 Medium

   Epigenetic silencing of GIPC2 by promoter CpG methylation in AML was shown, and its forced re-expression induced apoptosis via PI3K/AKT pathway suppression, extending the tumor-suppressive function to hematologic malignancy.

   Evidence Bisulfite sequencing, decitabine-mediated derepression, overexpression in HL-60 cells with phospho-AKT immunoblotting

   PMID:37212125

   Open questions at the time

   • Mechanism by which GIPC2 inhibits PI3K/AKT is not identified—no direct target shown
   • Only a single AML cell line tested
   • No in vivo validation of anti-leukemic effect
6. 2026 Medium

   GIPC2 was revealed as a metabolic-epigenetic coupling factor: its PDZ domain binds PKM2 and promotes PKM2 nuclear translocation, where PKM2 activates SREBP1 to drive lipogenic gene expression and adipogenic differentiation of mesenchymal stem cells.

   Evidence Co-IP with PDZ domain mapping, nuclear fractionation, SREBP1 reporter assays, knockdown/overexpression in UC-MSCs

   PMID:41500998

   Open questions at the time

   • Whether GIPC2 physically escorts PKM2 into the nucleus or merely stabilizes it there is unresolved
   • Relevance to in vivo adipogenesis or metabolic disease not tested
   • Single lab study; awaits independent replication

• A unifying mechanism explaining how GIPC2 selectively engages different partners (Fzd7, IGFR, PKM2, NONO) and produces opposing biological outputs (pro-proliferative vs. tumor-suppressive) across tissue contexts remains undefined.
• No structural model of GIPC2 PDZ domain bound to any partner
• No systematic interactome study to define the full partner repertoire
• No genetic model (knockout mouse) characterizing organismal phenotype